Skip to main content

Leukine Side Effects

Generic name: sargramostim

Medically reviewed by Drugs.com. Last updated on Mar 10, 2023.

Note: This document contains side effect information about sargramostim. Some dosage forms listed on this page may not apply to the brand name Leukine.

Applies to sargramostim: injection powder for solution.

Serious side effects of Leukine

Along with its needed effects, sargramostim (the active ingredient contained in Leukine) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking sargramostim:

More common

Incidence not known

Other side effects of Leukine

Some side effects of sargramostim may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Incidence not known

For Healthcare Professionals

Applies to sargramostim: injectable powder for injection, injectable solution.

General

The type and frequency of adverse events following induction in patients with acute myelogenous leukemia (AML) were similar between those treated with this drug and those taking placebo.[Ref]

Other

Very common (10% or more): Fever (up to 95%), mucous membrane disorder (75%), asthenia (up to 66%), malaise (57%), edema (up to 34%), chills (up to 25%), pain (17%), chest pain (15%), peripheral edema (up to 15%)[Ref]

Gastrointestinal

Very common (10% or more): Nausea (up to 90%), diarrhea (up to 89%), vomiting (up to 85%), stomatitis (up to 62%), abdominal pain (38%), gastrointestinal disorder (37%), gastrointestinal hemorrhage (up to 27%), dyspepsia (17%), hematemesis (13%), dysphagia (11%)

Common (1% to 10%): Constipation, abdominal distention[Ref]

Dermatologic

Very common (10% or more): Alopecia (up to 73%), rash (up to 70%), pruritus (23%)

Common (1% to 10%): Petechia, sweats[Ref]

Immunologic

Very common (10% or more): Infection (65%), allergy (12%), sepsis (11%)

Common (1% to 10%): Neutralizing antibodies

Frequency not reported: Allergic reaction, anaphylactoid reaction[Ref]

Metabolic

Very common (10% or more): Anorexia (up to 54%), glucose high (41%), weight loss (37%), hyperglycemia (25%), cholesterol high (17%), hypomagnesemia (15%)

Common (1% to 10%): Calcium low, weight gain[Ref]

Nervous system

Very common (10% or more): Headache (up to 36%), central nervous system disorder (11%), paresthesia (11%)

Frequency not reported: Dizziness

Postmarketing reports: Fainting[Ref]

Cardiovascular

Very common (10% or more): Hypertension (34%), hemorrhage (up to 29%), pericardial effusion (25%), hypotension (13%), tachycardia (11%)

Postmarketing reports: Arrhythmia, thrombosis[Ref]

Hepatic

Very common (10% or more): Bilirubinemia (30%), liver damage (13%), ALT increased (13%)

Common (1% to 10%): Alkaline phosphatase increased

Postmarketing reports: Transient liver function abnormalities[Ref]

Respiratory

Very common (10% or more): Dyspnea (28%), pharyngitis (23%), lung disorder (20%), epistaxis (17%), dyspnea (15%), rhinitis (11%)[Ref]

Hematologic

Very common (10% or more): Albumin low (27%), blood dyscrasia (25%), thrombocytopenia (19%), leukopenia (17%)

Common (1% to 10%): Agranulocytosis

Frequency not reported: Anemia, serum proteins low, prothrombin time prolonged, progressive increase in circulating monocytes and promonocytes and blasts in the marrow

Postmarketing reports: Eosinophilia[Ref]

Renal

Very common (10% or more): BUN high (23%), creatinine increased (15%)

Common (1% to 10%): Kidney function abnormal[Ref]

Musculoskeletal

Very common (10% or more): Bone pain (21%), arthralgia (up to 21%), myalgia (18%)

Common (1% to 10%): Back pain

Postmarketing reports: Joint pain[Ref]

Genitourinary

Very common (10% or more): Urinary tract disorder (14%)

Common (1% to 10%): Hematuria[Ref]

Psychiatric

Very common (10% or more): Insomnia (11%), anxiety (11%)[Ref]

Ocular

Very common (10% or more): Eye hemorrhage (11%)[Ref]

Local

Postmarketing reports: Injection site reactions[Ref]

References

1. Product Information. Leukine (sargramostim). Immunex Corporation. 2001.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.